Table 4.

The trend and correlation between the prevalence of CRPA and the rate of rational carbapenem use (or the consumption of carbapenems) during 2010–2017

	Trend	Slope (β)	P	Correlation with CRPA
				Coefficient	P
The prevalence of CRPA a	Stable	−0.006	0.51	/	/
The rate of rational of carbapenem use	Stable	0.004	0.73	−0.553	0.026*
The consumption of carbapenems b	Increasing	0.051	0.00	0.071	0.795

NOTE. All of the data were calculated per quarter in the second half of the year

^aCRPA, carbapenem-resistant Pseudomonas aeruginosa

^bThe consumption of carbapenems was expressed as defined daily doses per 1000 patients per day (DDDs/1000 PDs)